Currently Viewing:
American Diabetes Association (ADA) 2017
Dr Alan Carter on Biosimilars in the Insulin Market
July 27, 2017
Dr Eda Cengiz on New Technologies in Diabetes Management
July 26, 2017
Robby Booth of Glytec Discusses the Importance of Data-Sharing Capabilities
July 24, 2017
Dr Andrew Rhinehart: Improving Intermediate Outcomes in Diabetes Research
July 20, 2017
WellDoc Data Offer Promise for Integrating Diabetes Data Into Workflow
July 17, 2017
Currently Reading
Dr Alan Carter on the Steps to Managing Rising Insulin Costs
July 17, 2017
Nina Brown-Ashford: DPP Will Improve Care and Costs for Prediabetes Patients
July 06, 2017
Dr Alan Carter on Increasing Insulin Costs
July 04, 2017
Dr William Polonsky on Diabetes Patients' Treatment Satisfaction and Insulin Adherence
June 29, 2017
Dr Eda Cengiz on Improvements in Closed-Loop Systems
June 26, 2017
With Glytec, Hospital Moves to Basal-Bolus Insulin, Saves $9.7 Million
June 21, 2017
Raymie McFarland Discusses Findings From Glytec's Basal-Bolus Insulin Study
June 21, 2017
Sanofi Presents New Results for Insulin GLP-1 Combo Soliqua
June 13, 2017
Dr Bruce Neal Discusses Canagliflozin's Potential for Heart Failure Prevention
June 13, 2017
Dr Eda Cengiz Explains Artificial Pancreas Systems' Implications for Patients and Clinicians
June 13, 2017
CGM "Debate" Finds Benefits, Barriers to Uptake for Type 2 Diabetes
June 12, 2017
CANVAS Finds Lower Risk of CV Events for Invokana
June 12, 2017
Phase 3 Results Show Lower A1C for Ertugliflozin, Combined With Metformin and With Sitagliptin
June 12, 2017
Heart Failure Needs More Attention in Diabetes Drug Trials, Expert Says
June 11, 2017

Dr Alan Carter on the Steps to Managing Rising Insulin Costs

Legislators and Congress need to be pressured to achieve more price transparency in order to manage the high costs on insulin says Alan Carter, PharmD, principal investigator and senior advisor at MRIGlobal, and adjunct faculty at University of MissouriĀ­—Kansas City School of Pharmacy.


Legislators and Congress need to be pressured to achieve more price transparency in order to manage the high costs on insulin says Alan Carter, PharmD, principal investigator and senior advisor at MRIGlobal, and adjunct faculty at University of Missouri­–Kansas City School of Pharmacy.

Transcript (slightly modified)

What steps can be taken to manage the rising costs of insulin?

I believe that the best step to take, and it’s just my opinion, is that we need to pressure legislators and Congress, or the Federal Trade Commission if it’s a more appropriate short step, to start regulating the pharmacy benefit manager (PBM) industry as if it were a utility. They are currently in a monopolistic state, they contribute very little to the impact on patients, other than getting in the way, they just simply facilitate payments. Because they maintain that infrastructure, and its very inexpensive to maintain, they make a disproportionate amount of money that does not get returned to the consumer in a significant fashion.

So, there is a lot of hidden things that get in the way and we need more transparency. The only way to get more transparency, I think, is to call them a utility and step in and say here is what you’re going to do. We are going to regulate how much you get to raise your prices because you are performing an essential consumer service that the backbone of the nation’s health is built on.

Do you expect these steps to occur in the coming years?

That will only happen if we take a village approach, where everybody pitches together and we recognize that the manufacturers may have to be more transparent on their pricing scales and the PBMs need to be more transparent. Everyone is going to have to lose a little. The PBMs will probably lose the most, which is not going to make them happy and they are going to put a lot of money into politician’s pockets to stop this from happening. I don’t know how to best do that but I think through the Federal Trade Commission and grassroots efforts, like through the American Diabetes Association and other organizations, the American Medical Association needs to be involved. Everybody needs to be on board of how to get this under control because it doesn’t just affect diabetes patients, it affects any patient on chronic care that’s using any brand-name product. 

How will stakeholders need to work together to bring insulin pricing under control?

It will take all of us working together and understanding that we’re going to disagree at times and we are going to agree at times to come to the best compromise possible. We can’t be Congress, we have to make a decision, whether it be the best one or not, make the best one we can at the time, get the most consensus, and move forward to the next step. You can’t eat an elephant in one bite, you have to do it one bite at a time, and we really are tackling an elephant right now in healthcare.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!